As a proof-of-concept for this platform, we leveraged our accelerated recombinant VACV generation methodology to generate a novel immunogenic VACV vector-based oncolytic virus delivering a bacterial cyclase to synthesize STING agonizing cyclic dinucleotides in the tumor microenvironment. Here, STING1 is linked to neoplasm.